FDA approves first generic version of Sabril tablets17 Jan 2019
Approval of generic vigabatrin tablets granted to Teva Pharmaceuticals USA.
The FDA has approved the first generic version of Sabril (vigabatrin) 500 mg tablets for treating complex partial seizures, also called focal seizures, as an adjunctive therapy (given with another primary treatment) in patients 10 years and older who have responded inadequately to several alternative (refractory) treatments.
"Prioritizing the approval of generic drugs to compete with medicines that face little or no competition is a key part of our efforts to support access and reduce drug costs to patients. The availability of high-quality generic alternatives of critically important medicines, once the period of patent protection or exclusivity has ended on the brand drug, helps advance access and saves consumers billions of dollars each year,” said FDA Commissioner Scott Gottlieb.
He added: “We know there has been past interest in developing a generic alternative to this product. Earlier this year, we also highlighted this drug, along with many others, on a list of off-patent, off-exclusivity branded drugs without approved generics, to clarify that there were no patents or exclusivities that should impede its approval. Today’s (16 January 2019) action demonstrates that there is an open pathway to approving products like this one. We’re especially focused on new policies aimed at making the generic review process more predictable, efficient and lower cost so we can entice more generic firms to enter this space, and help facilitate more generic drug launches after generic approvals. We know it’s not enough just to approve a record number of generic medicines. We also want to see firms launch these products so that patients can benefit from their availability, and we intend to take steps to advance these goals."
Last year, the FDA began to publish a list of inquiries from generic drug developers seeking the FDA’s assistance in obtaining samples from brand companies, which included Sabril, noting these brand companies were potentially blocking access to the samples of their brand products when the brand products are subject to limited distribution programs, including REMS.
The FDA has continued to emphasize that even in the case of limited distribution programs, there should be a path forward for generic drug development. Additionally, the FDA’s list of off-patent, off-exclusivity branded drugs without approved generics is an effort the FDA began in 2017 and will continue to refine and update periodically to ensure continued transparency around drug categories where increased competition has the potential to provide significant benefit to patients.
Vetter's Skokie facility expansion nears completion
17 Apr 2019
Expansions will help meet an increase in customer projects; a second extension is in the final planning stage.Read more
Catalent to acquire gene therapy leader Paragon Bioservices
16 Apr 2019
Will provide new expertise and capabilities in one of the fastest-growing areas of healthcare.Read more
Colorcon expands functional film coatings through the CR Alliance with DuPont
15 Apr 2019
The Aquacoat product line provides modified release drug profiles with the added benefit of global regulatory acceptance.Read more
Hovione Technology acquires global rights to new pulmonary inhaler device
15 Apr 2019
The Papillon DPI is a single-part, blister-based, reusable inhaler, suitable for both chronic and acute treatments.Read more
Exploristics surges ahead with £1m investment
15 Apr 2019
The loan will be used to develop KERUS Cloud - currently the only software that can simulate trials with multiple correlated outcomes - by integrating it into an intelligent software ecosystem.Read more
Catalent celebrates opening of second Shanghai facility
14 Apr 2019
Catalent’s two Shanghai locations will provide sponsors with an optimized supply solution for studies being undertaken in China, the Asia-Pacific region and globally.Read more
Global collaboration to innovate more natural and additive-free nutraceuticals
12 Apr 2019
Initiative will enable Sirio Pharma to keep abreast of regional trends, new ingredients, dosage forms and claims to provide customers unique product ideas for line extensions.Read more
Isotype-specific secondary antibodies for improved signal detection
10 Apr 2019
Offers an alternative to cross-adsorbed secondary antibodies when absolute specificity is required.Read more
Sterling Pharma to acquire CiVentiChem in the US
9 Apr 2019
The acquisition will enhance the CDMO's chemistry development capabilities to support pre-clinical and early phase clinical supply.Read more
New China-based biotechs fueling growth in manufacturing across China
9 Apr 2019
New guidelines will see poorer quality manufacturers drop out of the market.Read more
Are you a supplier
Here's what we can do for you
- Generate quality leads for your business
- Stay visible for 365 days of the year
- Receive product inquiries and respond to meeting requests directly
- Improve company online presence through Search Engine Optimisation